Truvian Sciences Raises $105M Series C to Fund Development of Point-of-Care Testing Platform

“This is really about disrupting the way that industry is structured today,” CEO Jeff Hawkins said. “One of the core tenets to the approach we took to even developing this technology was [that] we wanted the point-of-care test to have similar dynamic ranges and similar precision and accuracy to the larger device.”